
Therapeutic Segment
Antidiabetic
CAS No.
960404-48-2
Regulatory Filing
-
Development Status
Under Development
Molecule Type
Small Molecule
Mechanism of Action
By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion.